SEATTLE--(뉴스와이어)--Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR product line. The new BCR solution and updates to the existing TCR product line expand Parse’s single cell portfolio and will enable researchers to study the immune repertoire at unprecedented resolution and scale.

Evercode BCR allows researchers to capture B cell receptor (BCR) sequences together with gene expression from the same cells. While existing tools struggle to capture the immense diversity of the BCR repertoire, Evercode BCR offers a breakthrough by measuring paired BCR sequences (both heavy and light chains) in up to one million cells in a single experiment. This scalable approach enables assignment of BCR clonotypes to various B-cell subtypes and activation states, providing unprecedented resolution and unleashing new capabilities in antibody discovery.

Parse has also expanded its Evercode TCR product line to enable detection of both mouse and human TCRs and dramatically improved performance. These updates provide improved sensitivity for both gene expression and TCR detection and are based on the recent release of the Version 3 chemistry for its flagship product, Evercode Whole Transcriptome.

Both Evercode BCR and TCR are compatible with fixation, which enables researchers to fix and store samples as they arrive and then later batch samples together in a single experiment. This enables time-courses and higher throughput experiments, while minimizing any potential batch effects between samples.

“Scaling up cell counts and sample numbers are crucial for achieving impactful results in single cell immune profiling,” said Parse Biosciences co-founder and CTO Charlie Roco. “We are excited about the new capabilities researchers will have with these solutions and to provide them with the unmatched scale required to uncover the vast repertoire diversity of the adaptive immune system.”

Parse team members will unveil additional details about Evercode BCR and updates to Evercode TCR at the upcoming American Association of Immunologists (AAI) annual meeting in Chicago on Sunday, May 5 at 10:45 AM in Exhibitor Workshop Theater #1, Hall F1.

About Parse Biosciences

Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach is enabling groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.

Founded based on a transformative technology invented at the University of Washington, Parse has raised over $100 million and is used in nearly 2,000 labs across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Capture, and a software tool for data analysis.

Headquartered in Seattle, Washington’s vibrant South Lake Union district, Parse Biosciences recently opened a 34,000 square foot headquarters and state-of-the-art laboratory.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240502001397/en/